Back to search
Symptomatic Transthyretin Amyloid Cardiomyopathy
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Symptomatic Transthyretin Amyloid Cardiomyopathy trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Symptomatic Transthyretin Amyloid Cardiomyopathy trials you may qualify forThis prospective study is designed to evaluate the efficacy, safety, and tolerability of ALXN2060 (also known as AG10), as well as to establish its pharmacokine…
Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Ph…
This prospective, multicenter open-label study will evaluate the long-term safety, tolerability, PK and PD of AG10 administered on a background of stable heart…
Phase 3 efficacy and safety study to evaluate acoramidis (AG10) HCl 800 mg administered orally twice a day compared to placebo in subjects with symptomatic Tran…
The objective of this prospective observational study is to periodically monitor pre-symptomatic subjects carrying a mutation of Transthyretin (TTR), identified…
This prospective, randomized, multicenter, double-blind, parallel group, placebo-controlled, dose-ranging study will evaluate the safety, tolerability, PK (Phar…